About

Our Mission

Meet the team committed to compassionate action on behalf of those suffering with disabling neuropsychiatric conditions.

Quote Created with Sketch.

Our mission is to develop novel therapies to dramatically improve the lives of people with psychiatric and neurological disorders.

Our Team

Karuna Therapeutics is bringing together a community of scientists, clinicians, and leaders with deep expertise in neuroscience and drug development.

Steve Paul, M.D.

Chairman of the Board, President and Chief Executive Officer

Stephen Brannan, M.D.

Chief Medical Officer

Andrew Miller, Ph.D.

Founder and Chief Operating Officer

Troy A. Ignelzi

Chief Financial Officer

Giorgio Attardo, Ph.D.

Vice President, CMC and Preclinical Development

Jim Audia, Ph.D.

Head of Medicinal Chemistry and Senior Adviser

Gregory T. Brophy, Ph.D.

Head of Regulatory and Senior Adviser

Jason Brown

Vice President of Corporate Finance

Christian Felder, Ph.D.

Vice President, Discovery Research

David Hewitt, M.D.

Senior Vice President, Medical

Jim Monn, Ph.D.

Vice President, Medicinal Chemistry

Advised by world experts in schizophrenia, Alzheimer’s disease, and neuroscience, we are positioned to meaningfully improve the lives of patients by delivering more effective and better tolerated treatments using a completely new mechanism of action (MOA).

Board of Directors

Steve Paul, M.D.

Chairman of the Board, President and Chief Executive Officer

Edmund Harrigan, M.D.

Former SVP, Worldwide Safety & Regulatory, Pfizer, Inc.

Jim Healy, M.D., Ph.D.

General Partner, Sofinnova Investments

Jeff Jonas, M.D.

Chief Executive Officer, Sage Therapeutics

Atul Pande, M.D.

Former Senior Vice President, Head of Neuroscience and Senior Advisor, Pharmaceutical R&D at GlaxoSmithKline; Member, Karuna Therapeutics Scientific Advisory Board

Robert Nelsen, MBA

Co-Founder and Managing Director, Arch Venture Partners

Heather Preston, M.D.

Managing Partner, Pivotal bioVenture Partners

Scientific Advisory Board

Alan Breier, M.D.

Chief Clinical Advisor & Chair, Karuna Scientific Advisory Board; Senior Professor of Psychiatry, Indiana University Mental Health Research and Education; Vice-Chair for Clinical Research; Chief, IU Psychotic Disorders Program; Director, Prevention and Recovery Center (PARC), Indiana University School of Medicine

Richard Keefe, Ph.D.

Professor of Psychiatry, Psychology, and Neurosciences, Duke University Medical Center

Allan Levey, M.D., Ph.D.

Professor & Chair, Department of Neurology at Emory University; Director, Goizueta Alzheimer’s Disease Research Center

Jeffrey Lieberman, M.D.

Lawrence C. Kolb Professor and Chairman, Department of Psychiatry, Columbia University College of Physicians and Surgeons; Director, New York State Psychiatric Institute; Psychiatrist-in-Chief of the New York-Presbyterian Hospital – Columbia University Medical Center.

Atul Pande, M.D.

Former Senior Vice President, Head of Neuroscience and Senior Advisor, Pharmaceutical R&D at GlaxoSmithKline; Board Member, Karuna Therapeutics

William Z. Potter, M.D., Ph.D.

Former VP, Translational Neuroscience, Merck; Former Head of Early Clinical Development, Eli Lilly

Anantha Shekhar, M.D., Ph.D.

Director, Indiana Clinical & Translational Sciences Institute; Distinguished Professor of Psychiatry, of Neurobiology and of Pharmacology & Toxicology;  August M. Watanabe Professor of Medical Research, and Executive Associate Dean for Research Affairs at the Indiana University School of Medicine

Carol A. Tamminga, M.D.

Lou and Ellen McGinley Distinguished Chair and the McKenzie Chair in Psychiatry at the University of Texas Southwestern Medical School; Chairman of the Department of Psychiatry; Chief of the Translational Neuroscience Division in Schizophrenia at UT Southwestern

Top